Literature DB >> 20198481

Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics.

Gabor G Kovacs1, Gergo Botond, Herbert Budka.   

Abstract

Neuropathological diagnosis of neurodegenerative dementias evolved by adapting the results of neuroanatomy, biochemistry, and cellular and molecular biology. Milestone findings of intra- and extracellular argyrophilic structures, visualizing protein deposition, initiated a protein-based classification. Widespread application of immunohistochemical and biochemical investigations revealed that (1) there are modifications of proteins intrinsic to disease (species that are phosphorylated, nitrated, oligomers, proteinase-resistant, with or without amyloid characteristics; cleavage products), (2) disease forms characterized by the accumulation of a single protein only are rather the exception than the rule, and (3) some modifications of proteins elude present neuropathological diagnostic procedures. In this review, we summarize how neuropathology, together with biochemistry, contributes to disease typing, by demonstrating a spectrum of disorders characterized by the deposition of various modifications of various proteins in various locations. Neuropathology may help to elucidate how brain pathologies alter the detectability of proteins in body fluids by upregulation of physiological forms or entrapment of different proteins. Modifications of at least the five most relevant proteins (amyloid-beta, prion protein, tau, alpha-synuclein, and TDP-43), aided by analysis of further "attracted" proteins, are pivotal to be evaluated simultaneously with different methods. This should complement the detection of biomarkers associated with pathogenetic processes, and also neuroimaging and genetic analysis, in order to obtain a highly personalized diagnostic profile. Defining clusters of patients based on the patterns of protein deposition and immunohistochemically or biochemically detectable modifications of proteins ("codes") may have higher prognostic predictive value, may be useful for monitoring therapy, and may open new avenues for research on pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20198481     DOI: 10.1007/s00401-010-0658-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  24 in total

1.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

Review 2.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

Review 3.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

Review 4.  TDP-43 autoregulation: implications for disease.

Authors:  Mauricio Budini; Emanuele Buratti
Journal:  J Mol Neurosci       Date:  2011-06-18       Impact factor: 3.444

Review 5.  Category cued recall following controlled encoding as a neuropsychological tool in the diagnosis of Alzheimer's disease: a review of the evidence.

Authors:  Giovanni Augusto Carlesimo; Roberta Perri; Carlo Caltagirone
Journal:  Neuropsychol Rev       Date:  2010-11-18       Impact factor: 7.444

Review 6.  FTD and ALS: a tale of two diseases.

Authors:  R Ferrari; D Kapogiannis; E D Huey; P Momeni
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

Review 7.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

8.  Con: Can neuropathology really confirm the exact diagnosis?

Authors:  Kurt A Jellinger
Journal:  Alzheimers Res Ther       Date:  2010-05-07       Impact factor: 6.982

9.  Heroin abuse exaggerates age-related deposition of hyperphosphorylated tau and p62-positive inclusions.

Authors:  Gabor G Kovacs; Monika Cs Horvath; Katalin Majtenyi; Mirjam I Lutz; Yasmin L Hurd; Eva Keller
Journal:  Neurobiol Aging       Date:  2015-07-17       Impact factor: 4.673

10.  Clinical neuropathology practice news 3-2012: the "ABC" in AD-revised and updated guideline for the neuropathologic assessment of Alzheimer's disease.

Authors:  Gabor G Kovacs; Ellen Gelpi
Journal:  Clin Neuropathol       Date:  2012 May-Jun       Impact factor: 1.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.